Biomarkers for Huntington's Disease Improving Clinical Outcomes /
Huntington’s disease (HD) is a fatal, inherited, neurodegenerative disorder, characterized by chorea, motor instabilities, psychiatric manifestations and cognitive decline. Early genetic testing provides an opportunity for clinical interventions aimed at delaying onset and/or slowing progression of...
Salvato in:
| Ente Autore: | |
|---|---|
| Altri autori: | , |
| Natura: | Elettronico eBook |
| Lingua: | inglese |
| Pubblicazione: |
Cham :
Springer International Publishing : Imprint: Springer,
2023.
|
| Edizione: | 1st ed. 2023. |
| Serie: | Contemporary Clinical Neuroscience,
|
| Soggetti: | |
| Accesso online: | https://doi.org/10.1007/978-3-031-32815-2 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
Sommario:
- Molecular Biomarkers.Somatic instability/Telomeres,- Genetic modifiers
- Current clinical trial biomarkers.-Pharmacodynamic biomarkers for Htt-lowering therapeutics.-Inflammatory biomarkers.-Sleep dysregulation markers.-Mitochondrial/Oxidative stress biomarkers.-Microbiomics
- Metabolomics.-Proteomics.-Transcriptomics.-Lipidomics.-Imaging marker overview.-Retinal imaging biomarkers
- MRI - non-invasive functional MRI measures
- The evolution of clinical trial methodology.-Digital biomarkers
- The future of telehealth
- Summary and future trends.